Academic Journal
Genetics and Screening in Prostate Cancer.
| Τίτλος: | Genetics and Screening in Prostate Cancer. |
|---|---|
| Συγγραφείς: | Partuzo JGR; Department of Urology, Georgetown University School of Medicine, Washington, DC, USA., Mora-Garijo B; Department of Urology, Medstar Georgetown University Hospital, Washington Hospital Center, Washington, DC, USA., Hwang J; Department of Urology, Georgetown University School of Medicine, Washington, DC, USA. Electronic address: Jonathan.J.Hwang@medstar.net. |
| Πηγή: | The Surgical clinics of North America [Surg Clin North Am] 2026 Aug; Vol. 106 (4), pp. 603-617. Date of Electronic Publication: 2026 May 27. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: W.B. Saunders Country of Publication: United States NLM ID: 0074243 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-3171 (Electronic) Linking ISSN: 00396109 NLM ISO Abbreviation: Surg Clin North Am Subsets: MEDLINE |
| Imprint Name(s): | Publication: Philadelphia, PA : W.B. Saunders Original Publication: Philadelphia. |
| Ιατρικοί όροι (MeSH): | Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/diagnosis , Genetic Testing*/methods , Early Detection of Cancer*/methods, Humans ; Male ; Genetic Predisposition to Disease ; Genetic Risk Score ; Prognosis |
| Περίληψη: | Prostate cancer is a highly prevalent and heritable malignancy with marked disparities in incidence, stage at diagnosis, and mortality among minority populations. While localized disease carries an excellent prognosis, outcomes decline sharply in advanced and metastatic cases, underscoring the need for improved risk stratification. This article reviews the role of germline and somatic genetic alterations in prostate cancer development, prognosis, and treatment selection. It outlines current guideline-based indications for genetic testing, emerging evidence supporting broader testing strategies, and evolving tools including polygenic risk scores, tumor-derived genomic classifiers, digital histopathology platforms, and circulating tumor DNA. (Copyright © 2026 Elsevier Inc. All rights reserved.) |
| Competing Interests: | Disclosures The authors have nothing to disclose. |
| Contributed Indexing: | Keywords: Germline genetic testing; Health disparities; Polygenic risk scores; Precision oncology; Prostate cancer; Somatic mutations |
| Entry Date(s): | Date Created: 20260708 Date Completed: 20260708 Latest Revision: 20260708 |
| Update Code: | 20260709 |
| DOI: | 10.1016/j.suc.2026.03.008 |
| PMID: | 42419315 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!